Werewolf Therapeutics, Inc. (HOWL) Misses Q2 EPS by 5c

Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q2 EPS of ($0.43), $0.05 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $1.14 million versus the consensus estimate of $841.78 thousand.

For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.

You May Also Be Interested In

• Tesla readies August launch of CyberCab - The Information
• SK Hynix (SKHY) call put ratio 1.1 calls to 1 put as share price up 2.6%
• Taranis Announces New Critical Minerals By-Product Findings at the Thor and Ajax Mines